AbCellera Biologics Inc. (ABCL) News
Filter ABCL News Items
ABCL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABCL News Highlights
- ABCL's 30 day story count now stands at 13.
- Over the past 25 days, the trend for ABCL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ABCL are EYE, PAY and PLRX.
Latest ABCL News From Around the Web
Below are the latest news stories about ABCELLERA BIOLOGICS INC that investors may wish to consider to help them evaluate ABCL as an investment opportunity.
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023VANCOUVER, British Columbia, January 24, 2023--AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 |
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately. |
AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS RatingA Relative Strength Rating upgrade for AbCellera Biologics shows improving technical performance. |
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture PatentVANCOUVER, British Columbia, January 20, 2023--AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent |
Does AbCellera Biologics (NASDAQ:ABCL) Deserve A Spot On Your Watchlist?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks... |
AbCellera Biologics Inc. (NASDAQ:ABCL) stock crossing the finish line todayIn the current trading session, AbCellera Biologics Inc.’s (ABCL) stock is trading at the price of $10.73, a gain of 1.76% over last night’s close. So, the stock is trading at a price that is -28.36% less than its 52-week high of $14.97 and 97.88% better than its 52-week low of $5.42. Based on the […] |
Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
AbCellera (ABCL) Stock: My Updated Current Valuation EstimateIn this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. See why I''m fervently bullish on ABCL stock. |
AbCellera Biologics Inc.'s (NASDAQ:ABCL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?It is hard to get excited after looking at AbCellera Biologics' (NASDAQ:ABCL) recent performance, when its stock has... |
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023VANCOUVER, British Columbia, January 04, 2023--AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 |